Status:

COMPLETED

A Multiple Dose Study to Assess the Safety and Tolerability of BMS-963272 in Obese But Otherwise Healthy Adults

Lead Sponsor:

Bristol-Myers Squibb

Conditions:

Obese But Otherwise Healthy Participants

Eligibility:

All Genders

18-60 years

Phase:

PHASE1

Brief Summary

This study will assess the safety and tolerability of multiple doses of BMS-963272 in obese but otherwise healthy participants.

Eligibility Criteria

Inclusion

  • For more information regarding Bristol-Myers Squibb Clinical Trial participation, please visit www.BMSStudyConnect.com
  • Participants must be in good general health, in the opinion of the investigator, with no clinically significant deviation from normal in medical history, physical examination findings, ECGs, or laboratory results.
  • Participants must have a BMI of 30 kg/m2 to 40 kg/m2 inclusive
  • Women (not of childbearing potential) and men aged 18 to 60 years, inclusive

Exclusion

  • Previous participation in the current study
  • Inability or unwillingness to comply with protocol-defined restrictions or requirements regarding lifestyle, diet, concomitant medications, or other aspects of the study
  • Inability to tolerate the oLTT meal or to comply with oLTT testing conditions
  • Inability to tolerate oral medication
  • Inability to tolerate venipuncture and/or inadequate venous access
  • Women who are breastfeeding
  • Medical Conditions
  • History of lactose intolerance
  • Any significant (in the opinion of the investigator) acute or chronic illness
  • Type 1 or 2 diabetes
  • Evidence of organ dysfunction or any clinically significant deviation from normal in physical examination, vital signs, ECG, or clinical laboratory determinations beyond what is consistent with the target population
  • Previous/Concomitant Therapy
  • Previous exposure to BMS-963272
  • Other protocol-defined inclusion/exclusion criteria could apply

Key Trial Info

Start Date :

September 30 2019

Trial Type :

INTERVENTIONAL

Allocation :

ACTUAL

End Date :

February 10 2020

Estimated Enrollment :

36 Patients enrolled

Trial Details

Trial ID

NCT04116632

Start Date

September 30 2019

End Date

February 10 2020

Last Update

May 15 2020

Active Locations (1)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 1 (1 locations)

1

PRA Health Sciences - Lenexa

Lenexa, Kansas, United States, 66219